Patricia Warren Wittig, CRNP-BC | |
2704 20th St S, Suite 104, Homewood, AL 35209-1924 | |
(205) 412-8599 | |
(205) 383-2425 |
Full Name | Patricia Warren Wittig |
---|---|
Gender | Female |
Speciality | General Practice |
Location | 2704 20th St S, Homewood, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1568785483 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 1-033136 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
Patricia Warren Wittig, CRNP-BC 2704 20th St S, Suite 104, Homewood, AL 35209-1924 Ph: (205) 412-8599 | Patricia Warren Wittig, CRNP-BC 2704 20th St S, Suite 104, Homewood, AL 35209-1924 Ph: (205) 412-8599 |
News Archive
Students at a suburban St. Louis high school are being tested for HIV after an HIV-positive individual told health officials that as many as 50 students might have been exposed to the virus, the AP/Google.com reports.
A test to diagnose two very serious diseases such as ALS and FTD when the pathologies have not yet appeared, thereby providing doctors and patients with essential information tools to tackle them early and develop new treatments.
The Justice Department's formal appeal puts to rest speculation about the administration's legal strategy. In addition, Republican state attorneys general separately asked the Supreme Court for a verdict early next year. Many observers say the new timeline will make the court's ultimate finding a factor in the presidential election.
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.
› Verified 8 days ago